Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07077369 | WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07077798 | Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection | not yet recruiting | N/A | 234 | Wan-Guang ZhangOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07078292 |
| The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study |
| not yet recruiting |
| — |
| 400 |
| Tianjin Medical University Cancer Institute and HospitalOTHER |
| 0 |
| Jul 22, 2025 |
| clinicaltrials |
| NCT07078305 | Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment | not yet recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07075419 | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT07067450 | Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma | not yet recruiting | N/A | 98 | Sichuan UniversityOTHER | 0 | Jul 16, 2025 | clinicaltrials |
| NCT07064668 | Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study | not yet recruiting | Phase 2 | 300 | Tongji HospitalOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07062328 | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC(HP-BTC-002) | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07064447 | Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator | not yet recruiting | — | 260 | Germans Trias i Pujol HospitalOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07058649 | Downstaging Prediction Model for HCC | not yet recruiting | — | 369 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Jul 10, 2025 | clinicaltrials |
| NCT07059442 | Screening for Anal Cancer and Precancer in Women With HIV (SANCA)(SANCA) | not yet recruiting | N/A | 1,000 | Karolinska InstitutetOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT07049185 | QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma(QICE-ESCC) | not yet recruiting | Phase 2 | 35 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07045558 | HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC | not yet recruiting | — | 28 | RenJi HospitalOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06780553 | Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma(PROFI-CHOL) | not yet recruiting | — | 60 | University Hospital, BordeauxOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06194461 | LTFU for All Cell and Gene Therapy Studies(LOCUS) | not yet recruiting | — | 64 | AstraZenecaINDUSTRY | 4 | Jun 27, 2025 | clinicaltrials |
| NCT07038863 | Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France(Mondelta) | not yet recruiting | N/A | 2,000 | Hospices Civils de LyonOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06943768 | Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test | not yet recruiting | — | 9,654 | Fudan UniversityOTHER | 0 | Jun 24, 2025 | clinicaltrials |
| NCT07034118 | Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study | not yet recruiting | Phase 1 | 23 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07018063 | Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer(YOUNG-NEOS) | not yet recruiting | Phase 2 | 35 | zhoujingOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07014254 | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies | not yet recruiting | N/A | 20 | Xijing HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07010588 | Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk(SHORT) | not yet recruiting | N/A | 1,389 | Peking University People's HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07003776 | Evaluation of Tumor Budding In Colorectal Adenocarcinoma | not yet recruiting | — | 50 | Sohag UniversityOTHER | 0 | Jun 4, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT06994572 | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 141 | Captor Therapeutics S.A.INDUSTRY | 0 | May 29, 2025 | clinicaltrials |
| NCT06990620 | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC(TACE HCC) | not yet recruiting | Phase 1 | 56 | Fudan UniversityOTHER | 0 | May 25, 2025 | clinicaltrials |
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | not yet recruiting | Phase 2 | 120 | AkesoINDUSTRY | 0 | May 22, 2025 | clinicaltrials |
| NCT05660213 | A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer | not yet recruiting | — | 750 | Fudan UniversityOTHER | 0 | May 20, 2025 | clinicaltrials |
| NCT06980389 | Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC) | not yet recruiting | Phase 2 | 176 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06861894 | Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC | not yet recruiting | Phase 2 | 164 | Zhigang LiOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06971107 | Current Microsatellite Stability Results in Colon Cancer | not yet recruiting | — | 1,500 | Turkish Society of Colon and Rectal SurgeryOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971237 | SIRT and Peri-immunotherapy : a New Concept(IMSIRT) | not yet recruiting | — | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06958484 | Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence | not yet recruiting | Phase 2 | 60 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06942767 | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | not yet recruiting | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06946849 | Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study(SED-RO-ICC) | not yet recruiting | Phase 2 | 76 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06944496 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 3 | 616 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06938451 | Relationship Between FGF19 Overexpression and Disease Prognosis(FGF19) | not yet recruiting | — | 100 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06935175 | A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 53 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06903663 | The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting(MANIFEST-HCC) | not yet recruiting | — | 100 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06928415 | Efficacy and Safety of Liver Transplantation for Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: a Single-arm, Multicenter, Prospective Study (HCC-BDTT in LT) | not yet recruiting | — | 130 | Zhejiang UniversityOTHER | 0 | Apr 15, 2025 | clinicaltrials |
| NCT06923176 | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment(BRCSRRRHCCART) | not yet recruiting | Phase 4 | 704 | Zhiyun YangOTHER | 0 | Apr 11, 2025 | clinicaltrials |
| NCT06919510 | A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT06913218 | A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC | not yet recruiting | Phase 1 | 60 | AkesoINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911021 | 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma | not yet recruiting | N/A | 20 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | not yet recruiting | Phase 2 / Phase 3 | 100 | Zhejiang Cancer HospitalOTHER | 0 | Apr 4, 2025 | clinicaltrials |
| NCT06903871 | Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR) | not yet recruiting | Phase 2 | 190 | Hebei Medical University Fourth HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06903273 | Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma(TisGCS for BTC) | not yet recruiting | Phase 2 | 35 | National Cheng-Kung University HospitalOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06899477 | Pre-Operative Treatment in REseCTable COlon CanceR | not yet recruiting | Phase 3 | 714 | Dominik Paul ModestOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06900478 | Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC | not yet recruiting | Phase 2 | 25 | Hua LiOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06896396 | Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | Zhiyong HuangOTHER | 1 | Mar 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2025source: clinicaltrials